Oxford BioMedica (OTCMKTS:OXBDF – Get Free Report)’s share price reached a new 52-week low on Wednesday . The company traded as low as $6.10 and last traded at $6.15, with a volume of 6470 shares traded. The stock had previously closed at $7.15.
Analyst Ratings Changes
Separately, Zacks Research upgraded Oxford BioMedica to a “hold” rating in a research note on Wednesday, July 22nd. One research analyst has rated the stock with a Hold rating, According to data from MarketBeat, Oxford BioMedica currently has an average rating of “Hold”.
View Our Latest Stock Report on Oxford BioMedica
Oxford BioMedica Price Performance
About Oxford BioMedica
Oxford BioMedica is a clinical-stage gene and cell therapy company headquartered in Oxford, United Kingdom. The company specializes in the development, manufacturing and commercialization of lentiviral vector delivery systems for use in treating serious diseases. Its proprietary LentiVector® platform underpins both in-house development programs and third-party collaborations, enabling the stable integration of therapeutic genes into target cells.
In its research pipeline, Oxford BioMedica is advancing candidates across ophthalmology, neuroscience and oncology indications.
See Also
- Five stocks we like better than Oxford BioMedica
- Lithia’s Record Quarter Keeps the Bull Case Alive
- 3 Lesser-Known Quantum Plays the Market May Be Overlooking Right Now
- Gold.com’s Q4 Results Show Why This Stock Is More Than a Gold Bet
- Analog Devices Shows Why AI Is Not the Only Story Driving Chip Demand
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.
